KR900013965A - 상피소체 호르몬 합성 및 분비억제 - Google Patents

상피소체 호르몬 합성 및 분비억제 Download PDF

Info

Publication number
KR900013965A
KR900013965A KR1019900004135A KR900004135A KR900013965A KR 900013965 A KR900013965 A KR 900013965A KR 1019900004135 A KR1019900004135 A KR 1019900004135A KR 900004135 A KR900004135 A KR 900004135A KR 900013965 A KR900013965 A KR 900013965A
Authority
KR
South Korea
Prior art keywords
derivative
administered
oxa
epithelial
hyperactivity
Prior art date
Application number
KR1019900004135A
Other languages
English (en)
Other versions
KR0153532B1 (ko
Inventor
슬라토폴스키 에두아르도
Original Assignee
사노 하지메
쥬우 가이세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노 하지메, 쥬우 가이세이야꾸 가부시끼가이샤 filed Critical 사노 하지메
Publication of KR900013965A publication Critical patent/KR900013965A/ko
Application granted granted Critical
Publication of KR0153532B1 publication Critical patent/KR0153532B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

상피소체 호르몬 합성 및 분비억제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 생체내에서 혈청 Ca2+, PTH 및 1,25 -(OH)2D3생산 및 조절의 상관 관계를 나타낸 것이다.
제2도는 각종 용량의 OCT 및 1,25 -(OH)2D3에 대한 칼슘이동 반응을 나타낸 것이다.
제3도는 OCT 및 1,25- -(OH)2D3의 만성적 투여에 대한 칼슘이동 반응을 나타낸 것이다.

Claims (11)

  1. 유효량의 하기 일반식(I)의 비타민D3유도체를 상피소체기능 항진중 환자에게 투여함을 특징으로 하는, 상피소체 기능 항진증 치료방법.
    (식중, R1, R2및 R3는 동일 또는 상이한 것으로서 각각 수소 원자 또는 히드록실기를 나타내고, R4는 수소, 또는 히드록실기로 임의 치환될 수 있는 C4∼6알킬기를 나타낸다.)
  2. 제1항에 있어서, 유도체를 정맥내 투여하는 방법.
  3. 제1항에 있어서, 유도체를 경구투여하는 방법.
  4. 제1항에 있어서, 환자가 만성 신부전증에도 걸려 있으며, 상피소체 기능 항진증이 속발성 상피소체기능 항진증인방법.
  5. 제4항에 있어서, 환자가 신장 투석중이며, 유도체를 각 신장투석중에 투여하는 방법.
  6. 제1항에 있어서, 유도체를 일일 약 0.5㎍내지 약 5㎍에 상응하는 최초량으로 투여하는 방법.
  7. 제6항에 있어서, 유도체를 1회 투여에 약 1㎍내지 10㎍의 초기량으로 일주일에 3번 정맥내 투여하는 방법.
  8. 제1항에 있어서, 유도체가 22-옥사-1,25-(OH)2D3인 방법.
  9. 제5항에 있어서, 유도체가 22-옥사-1,25-(OH)2D3인 방법.
  10. 제8항에 있어서, 유도체가 22-옥사-1,25-(OH)2D3를 일일 약 0.5㎍내지 약5㎍에 상응하는 초기량으로 투여하는 방법.
  11. 제10항에 있어서, 유도체가 22-옥사-1,25-(OH)2D3를 1회 투여에 약 1㎍내지 약10㎍의 초기량으로 일주일에 3번 정맥내 투여하는 방법
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900004135A 1989-03-28 1990-03-27 상피소체 기능 항진증 치료용 약제 조성물 KR0153532B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/329,606 US4948789A (en) 1989-03-28 1989-03-28 Suppression of parathyroid hormone synthesis and secretion
US329606 1999-06-10

Publications (2)

Publication Number Publication Date
KR900013965A true KR900013965A (ko) 1990-10-22
KR0153532B1 KR0153532B1 (ko) 1998-11-16

Family

ID=23286199

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900004135A KR0153532B1 (ko) 1989-03-28 1990-03-27 상피소체 기능 항진증 치료용 약제 조성물

Country Status (15)

Country Link
US (1) US4948789A (ko)
EP (1) EP0390114B1 (ko)
JP (1) JPH0686382B2 (ko)
KR (1) KR0153532B1 (ko)
AT (1) ATE111737T1 (ko)
AU (1) AU618506B2 (ko)
CA (1) CA2013166C (ko)
DE (1) DE69012620T2 (ko)
DK (1) DK0390114T3 (ko)
ES (1) ES2063852T3 (ko)
HK (1) HK66895A (ko)
HU (1) HU211597A9 (ko)
IE (1) IE64949B1 (ko)
IL (1) IL93896A (ko)
ZA (1) ZA902353B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2229921B (en) * 1989-04-05 1992-12-16 Chugai Pharmaceutical Co Ltd Treatment for hyperparathyroidism with use of vitamin d derivatives
GB9017890D0 (en) 1990-08-15 1990-09-26 Leo Pharm Prod Ltd Chemical compounds i
GB9220272D0 (en) * 1992-09-25 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
JP2004504295A (ja) * 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド 安定化１α−ヒドロキシビタミンＤ
CA2420759A1 (en) * 2000-08-30 2003-02-27 Daishiro Miura Parathyroid hormone production inhibitors containing vitamin d3 derivatives
US7129230B2 (en) 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
EP1402893A4 (en) * 2001-07-03 2006-02-08 Chugai Pharmaceutical Co Ltd MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SECONDARY PARATHYROID GLAND HYPERFUNCTION AND MEDICAMENTS FOR TREATING CARDIOVASCULAR COMPLICATIONS RELATED TO THE TREATMENT OF SECONDARY PARATHYROID GLAND HYPERFUNCTION
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184112B1 (en) * 1984-11-27 1990-05-09 Chugai Seiyaku Kabushiki Kaisha Novel vitamin d derivatives and process for producing the same
US4997824A (en) * 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease

Also Published As

Publication number Publication date
ES2063852T3 (es) 1995-01-16
CA2013166A1 (en) 1990-09-28
DK0390114T3 (da) 1994-10-17
US4948789A (en) 1990-08-14
ATE111737T1 (de) 1994-10-15
KR0153532B1 (ko) 1998-11-16
IE64949B1 (en) 1995-09-20
EP0390114B1 (en) 1994-09-21
EP0390114A2 (en) 1990-10-03
CA2013166C (en) 2001-01-02
EP0390114A3 (en) 1991-10-30
HU211597A9 (en) 1995-12-28
DE69012620T2 (de) 1995-03-23
ZA902353B (en) 1990-12-28
IL93896A (en) 1994-10-21
JPH037231A (ja) 1991-01-14
AU5210690A (en) 1990-10-04
JPH0686382B2 (ja) 1994-11-02
HK66895A (en) 1995-05-12
AU618506B2 (en) 1991-12-19
DE69012620D1 (de) 1994-10-27
IE901083L (en) 1990-09-28

Similar Documents

Publication Publication Date Title
KR900013965A (ko) 상피소체 호르몬 합성 및 분비억제
KR890011837A (ko) 디데하이드로 비타민 d₃유도체
ZA85388B (en) Yanthine derivatives,processes for their preparation and pharmaceutical compositions containing them
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
KR940002210A (ko) 24-시클로프로판 비타민 d 유도체
US4364941A (en) Method for regulating bone metabolism of warm-blooded animals, and pharmaceutical compositions thereof
DE3362022D1 (en) Xanthine derivatives, process for their preparation and pharmaceutical compositions containing them
KR970702291A (ko) 에퀼린의 산 이성질화체로부터 제조된 에퀼린 이중결합 이성질체(Anequilin double bond isomer from the acid isomerization of equilin)
KR970707089A (ko) 18, 19-디노르-비타민 D 화합물(18,19-Dinor-Vitamin D Compounds)
FR2554346B1 (fr) Ensemble et procede pour l'administration de gangliosides et de leurs derives par inhalation et compositions pharmaceutiques les contenant
ES2236742T3 (es) Uso de compuestos de la 19-nor-vitamina d para la prevencion de la.
KR880009654A (ko) 아세트알데히드의 독성을 감소시키는 조성물 및 방법
US20050065088A1 (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone
SE8300855L (sv) Nya piperazin- och homopiperazinderivat, forfaranden for framstellning derav och farmaceutiska kompositioner innehallande dem
US7361664B2 (en) Vitamin D receptor antagonists and related compositions and methods of use
KR880004810A (ko) 소화성 궤양 치료제
US20050063992A1 (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen
KR880013562A (ko) 7-티아프로스타글란딘e₁ 또는 그의 유도체를 함유하는 당뇨병치료 조성물
KR880003914A (ko) 5-메틸-10,11-디하이드로-5H-디벤조-[a,d] 사이클로헵텐-5,10-이민의 유도체
KR890005113A (ko) 아자크로만 유도체
KR830009776A (ko) 세포 보호 유도방법
KR910011820A (ko) Ltb4 합성 저해제
KR910004192A (ko) 프로페니토인의 치료적 유효량을 함유하는 발작증 치료용 제약 조성물
KR880003623A (ko) 시알로실글리세로리피드로 된 신경장해질환 치료제
Dring et al. A kinetic study of the fate of SL 73033 (antrafenine) in the rat [proceedings]

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090518

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee